High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC
Mehmet Altan(The University of Texas MD Anderson Cancer Center), Jianjun Zhang(The University of Texas MD Anderson Cancer Center)
Cited by 13
Related Papers
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
|The Lancet Oncology|2016|1.1k
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
|Cancer Discovery|2023|181
Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery
|Immunity|2021|134
Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer
|npj Breast Cancer|2018|59